Home › Research › TREM2 and immune genetics
Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy
Inoue T, Saito S, Tanaka M, Yamakage H, Kusakabe T, Shimatsu A, Ihara M, Satoh-Asahara N.. Proceedings of the National Academy of Sciences of the United States of America, 2019-04-29
Topic: Brain proteins, microglia and lab models
Plain-language summary
Cerebral amyloid angiopathy (CAA) results from amyloid-β deposition in the cerebrovasculature. It is frequently accompanied by Alzheimer's disease and causes dementia. We recently demonstrated that in a mouse model of CAA, taxifolin improved cerebral blood flow, promoted amyloid-β removal from the brain, and prevented cognitive dysfunction when administered orally.
What this study adds
Evidence grade: Low
In a mouse model of cerebral amyloid angiopathy, oral taxifolin improved cerebral blood flow, promoted amyloid-β removal, and prevented cognitive dysfunction. This is an early animal study and does not yet show a treatment, cure, or prevention for Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Inoue, T., Saito, S., Tanaka, M., Yamakage, H., Kusakabe, T., Shimatsu, A., et al. (2019). Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.1901659116
Vancouver
Inoue T, Saito S, Tanaka M, Yamakage H, Kusakabe T, Shimatsu A, et al. Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy. Proceedings of the National Academy of Sciences of the United States of America. 2019. doi:10.1073/pnas.1901659116. PMID: 31036637.
BibTeX
@article{inoue2019-31036637,
author = {Inoue, T. and Saito, S. and Tanaka, M. and Yamakage, H. and Kusakabe, T. and Shimatsu, A. and Ihara, M. and Satoh-Asahara, N.},
title = {{Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy}},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
year = {2019},
doi = {10.1073/pnas.1901659116},
pmid = {31036637},
url = {https://doi.org/10.1073/pnas.1901659116}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- It is frequently accompanied by Alzheimer's disease and causes dementia.
- We recently demonstrated that in a mouse model of CAA, taxifolin improved cerebral blood flow, promoted amyloid-β removal from the brain, and prevented cognitive dysfunction when administered orally.
- Here we showed that taxifolin inhibited the intracerebral production of amyloid-β through suppressing the ApoE-ERK1/2-amyloid-β precursor protein axis, despite the low permeability of the blood-brain barrier to taxifolin.
- Higher expression levels of triggering receptor expressed on myeloid cell 2 (TREM2) were associated with the exacerbation of inflammation in the brain.
Why it matters
In a mouse model of cerebral amyloid angiopathy, oral taxifolin improved cerebral blood flow, promoted amyloid-β removal, and prevented cognitive dysfunction. This is an early animal study and does not yet show a treatment, cure, or prevention for Alzheimer's disease in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Proceedings of the National Academy of Sciences of the United States of America) |
| Journal's citation record | 4 / 4 | Proceedings of the National Academy of Sciences: journal h-index 1,167 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 80 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.9 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 5.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Noriko Satoh‐Asahara: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | National Cerebral and Cardiovascular Center: institution h-index 445 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31036637) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1073/pnas.1901659116
- PubMed: 31036637
- Original source →
- Free full text: Proceedings of the National Academy of Sciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.